Abcodia Ltd is a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer. The Company’s first product is the ROCA© Test for the early detection of ovarian cancer, and it is expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia’s offerings are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed. The company maintains exclusive commercial access to a biobank of five million serum samples donated from more than 200,000 individuals over a 10-year period and holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. Headquartered in Cambridge, U.K., the Company has operations in Boston, Mass. and a clinical laboratory in Memphis, Tenn.

Company Growth (employees)
Cambourne, GB
Size (employees)
20 (est)-4%
Abcodia was founded in 2010 and is headquartered in Cambourne, GB

Abcodia Office Locations

Abcodia has offices in Cambourne, Boston, Memphis
Cambourne, GB
Memphis, US
Boston, US

Abcodia Metrics

Abcodia Summary

Founding Date


Total Funding

$10.2 m

Latest funding size

$8.3 m

Time since last funding

almost 2 years


We estimate that Abcodia's latest funding round in May 2015 was $8.3 m. In total, Abcodia has raised $10.2 m

Abcodia Financials

We estimate that Abcodia's revenue is £568.3 k in FY, 2015
FY, 2015


£568.3 k

Cost of sales

£28.5 k

Gross profit

£539.7 k

Gross profit Margin, %


Operating expense total

£3.3 m
We estimate that Abcodia's current employees are approximately 22% female and 78% male.

Abcodia Online Presence

Abcodia Company Life

You may also be interested in